Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hajarossadat Ghaderi
Observed name:
Hajarsadat Ghaderi
Institution:
Pasteur Institute of Iran
Observed institutions:
Islamic Azad University, Tehran,
Pasteur Institute of Iran,
Islamic Azad University, Science and Research Branch
ORCID:
0000-0001-5679-9550
Observed ORCID:
0000-0001-5679-9550
OpenAlex ID:
A5085162946
Receptor tyrosine kinase inhibitors in cancer
2023
·
Nasim Ebrahimi
, Elmira Fardi
, et al.
·
Cellular and Molecular Life Sciences
·
154
PDF
Nanobodies as novel therapeutic agents in envenomation
2018
·
Ehsan Alirahimi
, Fatemeh Kazemi-Lomedasht
, et al.
·
Biochimica et Biophysica Acta (BBA) - General Subjects
·
46
Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy
2020
·
Reyhaneh Roshan
, Shamsi Naderi
, et al.
·
Molecular Immunology
·
33
PDF
Selection and characterization of specific nanobody against neuropilin-1 for inhibition of angiogenesis
2020
·
Shamsi Naderi
, Reyhaneh Roshan
, et al.
·
Molecular Immunology
·
19
PDF
Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis
2022
·
Ayda Hassanzadeh Eskafi
, Akbar Oghalaei
, et al.
·
Immunopharmacology and Immunotoxicology
·
17
Recombinant antibody fragment therapeutics: Current status and future prospects of scFv, nanobody, and mimotopes
2023
·
Hajarossadat Ghaderi
, Atefeh Alipour
, et al.
·
Journal of Drug Delivery Science and Technology
·
14
Urtica dioica agglutinin (UDA) as a potential candidate for inhibition of SARS-CoV-2 Omicron variants: In silico prediction and experimental validation
2023
·
Fatemeh Sabzian-Molaei
, Seyedrafi Hosseini
, et al.
·
Phytomedicine
·
9
PDF
In Vivo Tumor Therapy with Novel Immunotoxin Containing Programmed Cell Death Protein-1 and Diphtheria Toxin
2021
·
Abbas Mousavi
, Alireza Sabouri
, et al.
·
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
·
8
In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin.
2022
·
Mohammad Hosseininejad-Chafi
, Ehsan Alirahimi
, et al.
·
PubMed Central
·
7
Expression and purification of SARS-CoV-2 receptor binding domain in Escherichia coli for diagnostic and therapeutic purposes
2024
·
Hajarossadat Ghaderi
, Alireza Shoari
, et al.
·
Research in Pharmaceutical Sciences
·
5
Evaluation of Genes and Molecular Pathways Involved in Pathogenesis of Sickle Cell Anemia: A Bioinformatics Analysis and Future Perspective
2024
·
Reza Maddah
, Sareh Etemad
, et al.
·
Iranian Journal of Public Health
·
3
Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model
2023
·
Shima Salehi
, Hajarossadat Ghaderi
, et al.
·
Iranian journal of pharmaceutical research
·
2
PDF
Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein.
2021
·
Hajarossadat Ghaderi
, Zahra Noormohammadi
, et al.
·
PubMed Central
·
2
In Vitro and In Vivo Studies of a Heminecrolysin Toxin–VEGF Fusion Protein as a Novel Therapeutic for Solid Tumor Targeting
2022
·
Zahra Naderiyan
, Nazli Sotoudeh
, et al.
·
Molecular Biotechnology
·
1
Specific Targeting of Zinc Transporter LIV-1 with Immunocytokine Containing Anti-LIV-1 VHH and Human IL-2 and Evaluation of its In vitro Antitumor Activity
2024
·
Rada Dehghan
, Arezoo Beig Parikhani
, et al.
·
Current Pharmaceutical Design
Prostate Cancer and WNT/STAT3 Signaling
2024
·
Sareh Etemad
, Mahdokht Sadat Manavi
, et al.
·
Springer eBooks
Development of polyclonal heavy chain antibodies targeting programmed death ligand-1.
2023
·
Akbar Oghalaie
, Alireza Shoari
, et al.
·
PubMed Central
PDF
Preparation of heavy chain polyclonal antibody against zinc transporter SLC39A6 and its diagnostic application
2021
·
Hajarossadat Ghaderi
, Zahra Noormohammadi
, et al.
·
DOAJ (DOAJ: Directory of Open Access Journals)
Show more works
View as search
Works count:
19
Citation count:
320
H-index:
8
I10-index:
6
Year
Topic
Type
